{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:04:52Z","timestamp":1780409092237,"version":"3.54.1"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Pasireotide-LAR represents a novel therapeutic option for patients with Cushing\u2019s disease (CD). Its efficacy and safety were assessed in clinical trials; however, the real-world evidence is still scarce. Methods: The study aimed to evaluate the impact of 12-month pasireotide-LAR therapy on disease control, glucose metabolism, lipid profiles, and adverse effects in a real-life setting. We retrospectively studied prospectively collected data of patients with persistent or recurrent CD administered with pasireotide-LAR in a single pituitary center. Results: Mean urinary free cortisol (mUFC) showed a sustained decrease from baseline, with the most pronounced decrease in the first 3 months of therapy (p = 0.007). The analysis of mean late-night salivary cortisol showed fluctuations over time, with the largest mean reduction in mLNSC at 3 months. During the therapy, an improvement in blood pressure control was observed, with a significant decrease in systolic blood pressure during the first 6 months of treatment (p = 0.005). Hyperglycemia was the most common adverse effect. Fasting plasma glucose and glycated hemoglobin (HbA1c) showed a gradual increase during pasireotide-LAR treatment, with the HbA1c significantly increasing at the last follow-up (p = 0.04). Conclusions: Pasireotide-LAR is an effective alternative treatment in selected patients with CD. Pasireotide-LAR is overall safe and well tolerated, with hyperglycemia being the most common but manageable adverse event.<\/jats:p>","DOI":"10.3390\/jcm14082794","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T03:27:46Z","timestamp":1744946866000},"page":"2794","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Experience with Pasireotide-LAR in Cushing\u2019s Disease: Single-Center 12-Month Observational Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-4827","authenticated-orcid":false,"given":"Lukasz","family":"Dzialach","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, 03-242 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta","family":"Respondek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Mazovian Brodnowski Hospital, 03-242 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-4624","authenticated-orcid":false,"given":"Przemyslaw","family":"Witek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, 03-242 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on Diagnosis and Management of Cushing\u2019s Disease: A Guideline Update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing Syndrome: A Review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s11102-022-01245-9","article-title":"Quality of Life Impairment after a Diagnosis of Cushing\u2019s Syndrome","volume":"25","author":"Webb","year":"2022","journal-title":"Pituitary"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e13113","DOI":"10.1111\/jne.13113","article-title":"Long-term Morbidity and Mortality in Patients with Cushing\u2019s Syndrome","volume":"34","author":"Braun","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gilis-Januszewska, A., Bogus\u0142awska, A., Rzepka, E., Ziaja, W., and Hubalewska-Dydejczyk, A. (2022). Individualized Medical Treatment Options in Cushing Disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1060884"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing\u2019s Disease: Adrenal Steroidogenesis Inhibitors","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","article-title":"Somatostatin and Dopamine Receptors as Targets for Medical Treatment of Cushing\u2019s Syndrome","volume":"10","author":"Feelders","year":"2009","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and Safety of Once-Monthly Pasireotide in Cushing\u2019s Disease: A 12 Month Clinical Trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s11102-022-01238-8","article-title":"Pituitary Acting Drugs: Cabergoline and Pasireotide","volume":"25","author":"Gadelha","year":"2022","journal-title":"Pituitary"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11102-019-00984-6","article-title":"Long-Term Safety and Efficacy of Subcutaneous Pasireotide in Patients with Cushing\u2019s Disease: Interim Results from a Long-Term Real-World Evidence Study","volume":"22","author":"Manetti","year":"2019","journal-title":"Pituitary"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","article-title":"The Medical Treatment with Pasireotide in Cushing\u2019s Disease: An Italian Multicentre Experience Based on \u201cReal-World Evidence\"","volume":"64","author":"Pivonello","year":"2019","journal-title":"Endocrine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.55730\/1300-0144.5335","article-title":"Pasireotide Treatment in Cushing\u2019s Disease: A Single Tertiary Center\u2019s Experience","volume":"52","author":"Durcan","year":"2022","journal-title":"Turk. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yedinak, C.G., Hopkins, S., Williams, J., Ibrahim, A., Cetas, J.S., and Fleseriu, M. (2017). Medical Therapy with Pasireotide in Recurrent Cushing\u2019s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00035"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alessi, Y., Alibrandi, A., Angileri, F.F., Ferra\u00f9, F., and Cannav\u00f2, S. (2025). Efficacy and Safety of Pasireotide in Patients with Cushing\u2019s Disease: A Monocentric Experience. Endocrine.","DOI":"10.1007\/s12020-025-04202-1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/EJE-19-0695","article-title":"Use of Late-Night Salivary Cortisol to Monitor Response to Medical Treatment in Cushing\u2019s Disease","volume":"182","author":"Pivonello","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-Month Phase 3 Study of Pasireotide in Cushing\u2019s Disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/ERC-22-0088","article-title":"Improved Pasireotide Response in USP8 Mutant Corticotroph Tumours in Vitro","volume":"29","author":"Albani","year":"2022","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 Mutational Status May Predict Drug Susceptibility in Corticotroph Adenomas of Cushing\u2019s Disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Treppiedi, D., Marra, G., Di Muro, G., Esposito, E., Barbieri, A.M., Catalano, R., Mangili, F., Bravi, F., Locatelli, M., and Lania, A.G. (2022). P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. Cancers, 14.","DOI":"10.3390\/cancers14102455"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/cen.15065","article-title":"A Long-term Prognosis Study of Human USP8 -mutated ACTH-secreting Pituitary Neuroendocrine Tumours","volume":"101","author":"Miao","year":"2024","journal-title":"Clin. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mondin, A., Manara, R., Voltan, G., Tizianel, I., Denaro, L., Ferrari, M., Barbot, M., Scaroni, C., and Ceccato, F. (2022). Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.935759"},{"key":"ref_22","first-page":"16928","article-title":"The Efficacy of Pasireotide Treatment in a Patient with Crooke Cell Adenoma","volume":"135","author":"Maliszewska","year":"2025","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Dzialach, L., Sobolewska, J., Respondek, W., Szamotulska, K., and Witek, P. (2023). Cushing\u2019s Disease: Long-Term Effectiveness and Safety of Osilodrostat in a Polish Group of Patients with Persistent Hypercortisolemia in the Experience of a Single Center. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123227"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","article-title":"Corticotroph Tumor Progression during Long-Term Therapy with Osilodrostat in a Patient with Persistent Cushing\u2019s Disease","volume":"24","author":"Moumdjian","year":"2021","journal-title":"Pituitary"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide Treatment Significantly Improves Clinical Signs and Symptoms in Patients with Cushing\u2019s Disease: Results from a Phase III Study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide\u2014A Novel Somatostatin Receptor Ligand after 20 Years of Use","volume":"23","author":"Bolanowski","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Feldt-Rasmussen, U., Bolanowski, M., Zhang, S.-L., Yu, Y., Witek, P., Kalra, P., Kietsiriroje, N., Piacentini, A., Pedroncelli, A.M., and Samson, S.L. (2024). Predictive Factors and the Management of Hyperglycemia in Patients with Acromegaly and Cushing\u2019s Disease Receiving Pasireotide Treatment: Post Hoc Analyses from the SOM230B2219 Study. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1250822"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","article-title":"Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients with Cushing\u2019s Disease: Results from an Open-Ended, Open-Label Extension Trial","volume":"18","author":"Schopohl","year":"2015","journal-title":"Pituitary"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing Pasireotide-Associated Hyperglycemia: A Randomized, Open-Label, Phase IV Study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing Hyperglycemia in Patients with Cushing\u2019s Disease Treated with Pasireotide: Medical Expert Recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mehlich, A., Bolanowski, M., Mehlich, D., and Witek, P. (2023). Medical Treatment of Cushing\u2019s Disease with Concurrent Diabetes Mellitus. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1174119"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Witek, P., Bolanowski, M., Kr\u0119towski, A., and G\u0142owi\u0144ska, A. (2024). Pasireotide-Induced Hyperglycemia in Cushing\u2019s Disease and Acromegaly: A Clinical Perspective and Algorithms Proposal. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1455465"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2147\/DMSO.S466328","article-title":"Management of Diabetes Mellitus in Acromegaly and Cushing\u2019s Disease with Focus on Pasireotide Therapy: A Narrative Review","volume":"17","author":"Falorni","year":"2024","journal-title":"DMSO"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"St\u00f6rmann, S., Meyh\u00f6fer, S.M., Groener, J.B., Faust, J., Schilbach, K., Seufert, J., and Verg\u00e8s, B. (2024). Management of Pasireotide-Induced Hyperglycemia in Patients with Acromegaly: An Experts\u2019 Consensus Statement. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1348990"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk Factors and Management of Pasireotide-Associated Hyperglycemia in Acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr. Connect."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:01Z","timestamp":1760030221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082794"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082794","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}